JP2010517544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010517544A5 JP2010517544A5 JP2009548617A JP2009548617A JP2010517544A5 JP 2010517544 A5 JP2010517544 A5 JP 2010517544A5 JP 2009548617 A JP2009548617 A JP 2009548617A JP 2009548617 A JP2009548617 A JP 2009548617A JP 2010517544 A5 JP2010517544 A5 JP 2010517544A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- hcmv
- chimeric
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 5
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000000890 antigenic effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000003149 assay kit Methods 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07101864 | 2007-02-07 | ||
| PCT/EP2008/000876 WO2008095677A1 (en) | 2007-02-07 | 2008-02-05 | Recombinant antigens of human cytomegalovirus (hcmv) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010517544A JP2010517544A (ja) | 2010-05-27 |
| JP2010517544A5 true JP2010517544A5 (enExample) | 2011-03-24 |
Family
ID=38229391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548617A Pending JP2010517544A (ja) | 2007-02-07 | 2008-02-05 | ヒトサイトメガロウイルス（ｈｃｍｖ）の組換え抗原 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100068229A1 (enExample) |
| EP (1) | EP2114991A1 (enExample) |
| JP (1) | JP2010517544A (enExample) |
| KR (1) | KR20090126256A (enExample) |
| CN (1) | CN101605808A (enExample) |
| AU (1) | AU2008213356A1 (enExample) |
| BR (1) | BRPI0807095A2 (enExample) |
| CA (1) | CA2677455A1 (enExample) |
| EA (1) | EA200970731A1 (enExample) |
| IL (1) | IL200187A0 (enExample) |
| MX (1) | MX2009008248A (enExample) |
| SG (1) | SG178761A1 (enExample) |
| WO (1) | WO2008095677A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120105543A (ko) | 2009-12-23 | 2012-09-25 | 4-안티바디 아게 | 인간 사이토메갈로바이러스에 대한 결합 멤버 |
| JP5712513B2 (ja) * | 2010-07-07 | 2015-05-07 | 富士レビオ株式会社 | ヒトサイトメガロウイルス感染の検出方法 |
| US20130288389A1 (en) * | 2011-01-18 | 2013-10-31 | Prionics Ag | Methods for amplification and detection of prions |
| CN102816246B (zh) * | 2012-09-04 | 2014-07-23 | 成都蓉生药业有限责任公司 | 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2019020480A1 (en) * | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL60184A (en) * | 1979-05-31 | 1984-05-31 | Schering Ag | Process for the specific cleavage of protein sequences from proteins |
| RU2023448C1 (ru) * | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
| CA2050425A1 (en) * | 1990-09-03 | 1992-03-04 | Yoshiaki Uda | Pharmaceutical composition and its mucous use |
| JP3626996B2 (ja) * | 1992-05-23 | 2005-03-09 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| DE69716305T2 (de) * | 1996-07-12 | 2003-06-26 | Organon Teknika B.V., Boxtel | Peptidereagenz zum nachweis von humanem cytomegalovirus (cmv) |
| US6306404B1 (en) * | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| AT408615B (de) * | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| WO2003010198A1 (en) | 2001-07-26 | 2003-02-06 | Kenton Srl | Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques |
-
2008
- 2008-02-05 CA CA002677455A patent/CA2677455A1/en not_active Abandoned
- 2008-02-05 CN CNA2008800045081A patent/CN101605808A/zh active Pending
- 2008-02-05 JP JP2009548617A patent/JP2010517544A/ja active Pending
- 2008-02-05 SG SG2012008769A patent/SG178761A1/en unknown
- 2008-02-05 BR BRPI0807095-4A2A patent/BRPI0807095A2/pt not_active IP Right Cessation
- 2008-02-05 KR KR1020097018587A patent/KR20090126256A/ko not_active Withdrawn
- 2008-02-05 AU AU2008213356A patent/AU2008213356A1/en not_active Abandoned
- 2008-02-05 US US12/525,800 patent/US20100068229A1/en not_active Abandoned
- 2008-02-05 EP EP08707547A patent/EP2114991A1/en not_active Withdrawn
- 2008-02-05 MX MX2009008248A patent/MX2009008248A/es not_active Application Discontinuation
- 2008-02-05 EA EA200970731A patent/EA200970731A1/ru unknown
- 2008-02-05 WO PCT/EP2008/000876 patent/WO2008095677A1/en not_active Ceased
-
2009
- 2009-07-30 IL IL200187A patent/IL200187A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113321739B (zh) | 一种covid-19亚单位疫苗及其制备方法与应用 | |
| JP2010517544A5 (enExample) | ||
| JP2010166921A5 (enExample) | ||
| RU2012155702A (ru) | Композиция микробактериальных антигенов | |
| RU2016133598A (ru) | Композиция микобактериального антигена | |
| CN113527522A (zh) | 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗 | |
| CN102180974B (zh) | 一种结核杆菌融合蛋白及其制备方法和应用 | |
| EP4267185A1 (en) | Constructs comprising single domain vhh antibodies against sars-cov-2 | |
| WO2009103752A1 (en) | Protein nanocarriers, process for obtaining them and applications | |
| RU2012137304A (ru) | Рекомбинантные белки для применения в вакцине, антитела к указанным белкам и диагностические и терапевтические способы, включающие указанное | |
| JP2017521654A5 (enExample) | ||
| Lin et al. | Molecular characterization of three major outer membrane proteins, TSA56, TSA47 and TSA22, in Orientia tsutsugamushi | |
| JP3809502B2 (ja) | ハンタウィルス抗原蛋白質およびモノクローナル抗体 | |
| CN106226520B (zh) | 结核分枝杆菌抗原蛋白Rv0865及其B细胞表位肽的应用 | |
| WO2016064060A1 (ko) | Ｐｃｖ２에 특이적인 단일클론항체 및 이를 이용한 ｐｍｗｓ의 진단 방법 | |
| CN102643349B (zh) | 携带乙肝病毒抗原表位的重组嵌合蛋白及其制备 | |
| Shen et al. | DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice | |
| CN102978219A (zh) | 一种弧菌交叉保护性抗原及其制备方法和应用 | |
| WO2022242432A1 (en) | Peptide vaccine for virus infection | |
| JP2004532011A (ja) | 微生物病原体の生物学的に活性な構造体を同定する方法 | |
| JP2004531235A5 (enExample) | ||
| Chaudhary et al. | Assessment of Cpa, Scl1 and Scl2 in clinical group A streptococcus isolates and patients from north India: an evaluation of the host pathogen interaction | |
| CN105218668A (zh) | 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用 | |
| CN102169122B (zh) | 一种用于诊断q热病的蛋白组合物 | |
| CN104193827B (zh) | 一种丙型肝炎病毒第一高变区融合抗原及其应用 |